FDA Relies On Short-Term Data To Approve Medtronic's Recapturable TAVR System
Executive Summary
The approval comes less than a week after FDA approved Edwards' Sapien 3 third-generation transcatheter aortic replacement valve. Both devices were approved based on short-term outcomes data instead of the two-year data FDA has required of TAVR systems in the past.
You may also be interested in...
OUS Approvals Analysis: Edwards, Medtronic, Ra Medical Headline A Very Slow Month For Non-US Approvals
Medical devices approved outside the US in October include Medtronic's CoreValve Evolut R, Edwards' Acumen Hypotension Probability Indicator, and two approvals – for two completely different indications – for Ra Medical Systems' excimer laser technology.
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.
BMS Has A Strong Pipeline, But Access Challenges Remain
Bristol Myers Squibb’s head of major markets, Monica Shaw, wants to improve patients’ access to lifesaving therapies. And the group has several new products ready to roll.